Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The endogenous defenses of the mouse heart against reactive oxygen metabolites were investigated. The activities of three enzymes capable of detoxifying activated oxygen were determined in both the heart and liver; cardiac muscle contains 150 times less catalase and nearly four times less superoxide dismutase than liver. Glutathione peroxidase activities were, however, similar to the two tissues. Assay of glutathione peroxidase in the heart after 6 wk of selenium depletion with both hydrogen peroxide and cumene hydroperoxide as substrates revealed a >80% drop in enzyme activity and gave no indication that murine cardiac tissue contains nonselenium-dependent glutathione peroxidase. The selenium-deficient state, which was characterized by markedly decreased cardiac glutathione peroxidase levels, led to significantly enhanced doxorubicin toxicity at a dose of 15 mg/kg i.p. Doxorubicin administration in selenium-sufficient animals resulted in a dose-dependent decrease in cardiac glutathione peroxidase activity; the decrease in enzyme activity lasted 72 h after 15 mg/kg i.p. In contrast, cardiac superoxide dismutase and hepatic superoxide dismutase and glutathione peroxidase were unaffected by this dose of doxorubicin. These results suggest that the major pathway in cardiac tissue for detoxification of reactive oxygen metabolites is via the concerted action of superoxide dismutase and selenium-dependent glutathione peroxidase. The latter enzyme may be depleted by a selenium-deficient diet or doxorubicin treatment, leaving the heart with limited mechanisms for disposing of hydrogen peroxide or lipid peroxides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
McCord, J. M., & Fridovich, I. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63504-5 · Cited by 12,952
Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
Paglia, D. E., & Valentine, W. N. (1967) · PubMed · Cited by 10,889
Misra, H. P., & Fridovich, I. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45228-9 · Cited by 9,097
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Statistical Methods in Medical Research.
Armitage, P. (1972) · Biometrics · doi:10.2307/2556182 · Cited by 4,029
Glutathione peroxidase activity in selenium-deficient rat liver
Lawrence, R. A., & Burk, R. F. (1976) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(76)90747-6 · Cited by 3,528
Fridovich (1978) · doi:10.1126/science.210504 · Cited by 3,329
Measurement of catalase activity in tissue extracts
Cohen, G., Dembiec, D., & Marcus, J. (1970) · Analytical Biochemistry · doi:10.1016/0003-2697(70)90083-7 · Cited by 1,209
THE EXTINCTION COEFFICIENTS OF THE REDUCED BAND OF PYRIDINE NUCLEOTIDES
Horecker, B. L., & Kornberg, A. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57268-9 · Cited by 1,122
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Molecular mechanisms of quinone cytotoxicity
O'Brien, P. J. (1991) · Chemico-Biological Interactions · doi:10.1016/0009-2797(91)90029-7 · Cited by 1,029
Jolly, S. R., Kane, W. J., Bailie, M. B., Abrams, G. D., & Lucchesi, B. R. (1984) · Circulation Research · doi:10.1161/01.res.54.3.277 · Cited by 900
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Self-citationŠimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Toxic drug effects associated with oxygen metabolism: Redox cycling and lipid peroxidation
Kappus, H., & Sies, H. (1981) · Experientia · doi:10.1007/bf01948335 · Cited by 642
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Self-citationMitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy
Wallace, K. B., Sardão, V. A., & Oliveira, P. J. (2020) · Circulation Research · doi:10.1161/circresaha.119.314681 · Cited by 599
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Potential health impacts of excessive flavonoid intake
Skibola, C. F., & Smith, M. T. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00304-x · Cited by 569
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Self-citationDoxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Free radical formation by antitumor quinones
Powis, G. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90162-7 · Cited by 423
Yet, S.-F., Tian, R., Layne, M. D., Wang, Z. Y., Maemura, K., Solovyeva, M., Ith, B., Melo, L. G., Zhang, L., Ingwall, J. S., et al. (2001) · Circulation Research · doi:10.1161/hh1401.093314 · Cited by 420
Kong, C.-Y., Guo, Z., Song, P., Zhang, X., Yuan, Y.-P., Teng, T., Yan, L., & Tang, Q.-Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65258 · Cited by 412
Lipid peroxidation and activity of antioxidant enzymes in diabetic rats
Kakkar, R., Kalra, J., Mantha, S. V., & Prasad, K. (1995) · Molecular and Cellular Biochemistry · doi:10.1007/bf01322333 · Cited by 395
Cardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007) · Molecular Interventions · doi:10.1124/mi.7.3.6 · Cited by 387
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Oxidative Stress and Diabetic Cardiomyopathy: A Brief Review
Cai, L., & Kang, Y. J. (2001) · Cardiovascular Toxicology · doi:10.1385/ct:1:3:181 · Cited by 376
In vivo damage of rat lungs by oxygen metabolites.
Johnson, K. J., Fantone, J. C., Kaplan, J., & Ward, P. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110149 · Cited by 359
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005) · Circulation · doi:10.1161/01.cir.0000160359.49478.c2 · Cited by 355
Lipid Peroxidation and Mechanisms of Toxicity
Horton, A. A., Fairhurst, S., & Bus, J. S. (1987) · CRC Critical Reviews in Toxicology · doi:10.3109/10408448709089856 · Cited by 339
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Dieterich, S., Bieligk, U., Beulich, K., Hasenfuss, G., & Prestle, J. (2000) · Circulation · doi:10.1161/01.cir.101.1.33 · Cited by 325
Kang, Y. J., Chen, Y., & Epstein, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12610 · Cited by 303
Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress
Angsutararux, P., Luanpitpong, S., & Issaragrisil, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/795602 · Cited by 288
Livrea, M., Tesoriere, L., Pintaudi, A., Calabrese, A., Maggio, A., Freisleben, H., D'Arpa, D., D'Anna, R., & Bongiorno, A. (1996) · Blood · doi:10.1182/blood.v88.9.3608.bloodjournal8893608 · Cited by 274
Role of reactive oxygen metabolites in experimental glomerular disease
Shah, S. V. (1989) · Kidney International · doi:10.1038/ki.1989.96 · Cited by 272
Metabolism and reactions of quinoid anticancer agents
Powis, G. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90105-7 · Cited by 270
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 269
Self-citationBrookins Danz, E. D., Skramsted, J., Henry, N., Bennett, J. A., & Keller, R. S. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.011 · Cited by 266
Mantawy, E. M., El-Bakly, W. M., Esmat, A., Badr, A. M., & El-Demerdash, E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.065 · Cited by 259
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 253
The iron paradigm of ischemic heart disease
Sullivan, J. L. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90887-9 · Cited by 241
Zhang, X., & Tan, B. K. (2000) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2000.03253.x · Cited by 240
“This enzyme scavenges O2–• anion (which is the first product of O2 radicals) to form H2O2 and, hence, diminishes the toxic effects due to this radical or other free radicals derived from secondary reactions.30 The O2–• anion is known to inactivate CAT31,32 and GSH-Px.33 Catalase has been regarded as a major determinan…”
BackgroundDaunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel-Sadron, G., & Londos-Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
“The specificity of the oxidative stress to the cardiac cells could be due to relatively low levels of antioxidant enzymes in heart [34].”
BackgroundMechanism of adriamycin cardiotoxicity: Evidence for oxidative stress
Olson, R. D., Boerth, R. C., Gerber, J. G., & Nies, A. S. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90001-1 · Cited by 211
Doxorubicin-Induced Cardiac Toxicity
Doroshow, J. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241210 · Cited by 198
Self-citationAnthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011) · Pediatric Cardiology · doi:10.1007/s00246-010-9878-3 · Cited by 179
“Finally, the heart has fewer natural antioxidants than other organs, and one of its key antioxidants, glutathione peroxidase, is depleted in the presence of anthracycline [17].”
BackgroundGovender, J., Loos, B., Marais, E., & Engelbrecht, A. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12176 · Cited by 176
“In addition, DXR reduces or inhibits the activity of the cells antioxidant defense system [89, 90].”
BackgroundCarvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
“…phenomenon, the difference in susceptibility may be due to the relatively low levels of superoxide dismutase , catalase, and glutathione peroxidase in cardiac tissue compared to liver (Doroshow et al., 1980) or because of the vastly greater numbers of mitochondria and higher energy FIG.”
BackgroundProtective effect ofSpirulina against doxorubicin-induced cardiotoxicity
Khan, M., Shobha, J. C., Mohan, I. K., Naidu, M. U. R., Sundaram, C., Singh, S., Kuppusamy, P., & Kutala, V. K. (2005) · Phytotherapy Research · doi:10.1002/ptr.1783 · Cited by 159
“…mice (Myers et al., 1977; Naidu et al., 2002) The heart is more susceptible to free radical-induced damage, because it has relatively low antioxidant enzymes such as superoxide dismutase and catalase (Doroshow et al., 1980; Simmons et al., 1989; Naidu et al., 2002; Abou-El-Hassan et al., 2003).”
BackgroundDoxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
“Due to their limited capacity to scavenge free radicals, cardiac myocytes are more prone to ROS-induced damage, possibly explaining why the heart is more susceptible to DOXinduced toxicity than other organs (74).”
Cai, L. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.06.007 · Cited by 99
OXIDATIVE STRESS AND THE PATHOGENESIS OF HEART FAILURE
Ball, A. M. M., & Sole, M. J. (1998) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70043-6 · Cited by 53
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Metadata
- Authors
- Doroshow, J. H., Locker, G. Y., & Myers, C. E.
- Venue
- Journal of Clinical Investigation
- Published
- 1980-01-01
- Volume
- 65
- Issue
- 1
- Pages
- 128-135
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1920198420
- Cited by
- 702
- References
- 32
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.